At a Glance: Departmental Evaluation Plan for the Public Health Agency of Canada and Health Canada, 2019-20 to 2023-24

thumbnail

Download the alternative format
(PDF format, 80 KB, 7 pages)

Date published: 2016-01

This document presents the Office of Audit and Evaluation's (OAE) Departmental Evaluation Plan (DEP) for 2019-20 to 2023-24 for the Public Health Agency of Canada (PHAC) and Health Canada (HC).

The DEP is updated annually to support the allocation of resources to a suite of evaluation projects over a five-year period, and is focused on Departmental and PHAC information needs. The development of this plan complies with requirements of the Treasury Board (TB) Policy on Results (July 1, 2016). The projects contained within this plan were selected to ensure compliance with legislation and policy, support information needs, and consider risks in order to ensure the optimal use of resources.

The Departmental Results Frameworks (DRF), program inventories, and performance information profiles developed by each organization have formed the basis for this plan.

Planning for Evaluation

Over the next five years, the OAE plans to conduct 51 evaluations, 19 of which will cover PHAC activities and 23 of which will cover HC activities. In addition, OAE will participate in nine horizontal evaluations led by other government departments or agencies. A yearly breakdown is provided in Table 1, while Table 2 provides an overview of the number of horizontal evaluations led by other government departments (OGDs) by year. Appendices A and B outline the direct program spending (DPS) by branch for all scheduled evaluation for the next five years for PHAC and for HC respectively.

Table 1 - Number of evaluations per fiscal year
2019-20 2020-21 2021-22 2022-23 2023-24 Total
PHAC 5 4 5Footnote 1 3 2 19
HC 5 3 6 5 4 23
Horizontal OGD led - 3 2 2 2 9
Total 10 10 13 10 8 51
Table 2 - Number of horizontal evaluations led by OGDs per fiscal year
2019-20 2020-21 2021-22 2022-23 2023-24 Total
Only PHAC activities - 1 - - 1 2
Only HC activities - 1 - - 1 2
Both PHAC and HC - 1 2 2 - 5
Total Horizontal 0 3 2 2 2 9
Appendix A- Coverage of Public Health Agency of Canada Direct Program Spending (DPS)
Program Evaluations planned in the next five years Fiscal year of approval 2019-20 spending covered by evaluation ($) Rationale for not evaluating program or spending
Core Responsibility Health Promotion and Chronic Disease Prevention ($257,822,279)

Health Promotion

($156,713,664)

Family Violence Investment 2019-20 998,290 N/A
Innovation Strategy 2019-20 5,981,592 N/A
Canadian Centre for Aging and Brain Health Innovation Contribution Program 2019-20 10,191,791 N/A
Children's Programs (CAPC, CPNP, FASD) 2020-21 85,725,347 N/A
Strategy to Prevent and Address Gender-based Violence 2020-21 14,506,669 N/A
Aboriginal Head Start in Urben and Northern Communities 2021-22 35,955,975 N/A
Roadmap for Canada's Official Languages: Education, Immigration, Communities 2021-22 2,835,000 N/A
Oral Health N/A - Low Need: Evaluation conducted within last seven years (2016-17).
Nutrition North Canada N/A 519,000 Low Need: These activities are part of the broader horizontal initiative, led by Indigenous Services Canada. There is low utility to assessing in isolation, but there is the potential that ISC will cover these activities as part of a broader horizontal evaluation, which will be determined in year 3 or 4 of this plan.

Chronic Disease Prevention

($33,684,068)

Multisectoral Partnerships 2019-20 30,252,223 N/A
PHAC's Tobacco Activities 2021-22 3,431,845 N/A

Evidence for Health Promotion, and Chronic Disease and Injury Prevention

($67,424,547)

Canadian Centre for Aging and Brain Health Innovation Contribution Program 2019-20 10,000,000 N/A
Innovation Strategy 2019-20 250,000 N/A
Multisectoral Partnerships 2019-20 1,433,000 N/A
Children's Programs (CAPC, CPNP, FASD) 2020-21 250,000 N/A
Evidence for Health Promotion, and Chronic Disease and Injury (including CPHO Report and CCDR) 2021-22 51,570,545 N/A
Canadian Drug and Substance Strategy 2021-22 1,000,000 N/A
National Collaborating Centres 2023-24 2,921,002 N/A
Core Responsibility Infectious Disease Prevention and Control ($207,886,062)

Laboratory Science Leadership and Services

($83,637,518)

Public Health Laboratories 2019-20 72,814,261 N/A
Canadian Food Safety Information Network 2022-23 3,228,668 N/A
Emergency Preparedness and Response 2022-23 1,260,000 N/A
Federal Initiative for HIV/AIDS in Canada (including STBBI activities) 2023-24 6,334,589 N/A

Communicable Diseases and Infection Control

($70,380,444)

Tuberculosis 2021-22 - N/A
Canadian Drug and Substances Strategy 2021-22 7,000,000 N/A
Health Care-Associated Infections 2022-23 27,218,076 N/A
Federal Initiative for HIV/AIDS in Canada (including STBBI activities) 2023-24 35,188,702 N/A
National Collaborating Centres 2023-24 973,666 N/A

Immunization

($35,349,498)

Immunization and Respiratory Infectious Diseases 2020-21 35,349,498 N/A

Foodborne and Zoonotic Diseases

($18,518,602)

Adapting to Climate Change 2020-21 4,842,412 N/A
Foodborne and Zoonotic Diseases 2022-23 12,702,524 N/A
National Collaborating Centres 2023-24 973,666 N/A
Core responsibility Health Security ($52,331,185)

Emergency Preparedness and Response

($35,501,051)

Emergency Preparedness and Response 2022-23 34,527,385 N/A
National Collaborating Centres 2023-24 973,666 N/A

Biosecurity

($9,130,012)

Biosecurity 2020-21 9,130,012 N/A

Border and Travel Health

($7,700,122)

Border and Travel Health Program 2021-22 7,700,122 N/A
Core Responsibility Other
Single Window Initiative (funding Sunset in 2017-18) 2020-21 - N/A
Appendix B- Coverage of Health Canada Direct Program Spending (DPS)
Program Evaluations planned in the next five years Fiscal year of approval 2019-20 spending covered by evaluation ($) Rationale for not evaluating program or spending
Core Responsibility Health Care Systems ($1,576,688,206)

Health Care Systems Analysis and Policy

($55,467,706)

Home Care and Mental Health Services Initiative 2021-22 11,349,706 N/A
Health Care Policy Contribution Program 2023-24 27,118,000 N/A
Pan-Canadian Health Organizations 2023-24 17,000,000 N/A

Access, Affordability, and Appropriate Use of Drugs and Medical Devices

($24,428,155)

Pan-Canadian Health Organizations 2023-24 24,248,155 N/A

Home, Community and Palliative Care

($651,075,395)

Home Care and Mental Health Services Initiative 2021-22 651,075,395 N/A

Mental Health

($465,325,395)

Home Care and Mental Health Services Initiative 2021-22 451,075,395 N/A
Pan-Canadian Health Organizations 2023-24 14,250,000 N/A

Substance Use and Addictions

($55,884,526)

Canadian Drugs and Substance Strategy 2021-22 55,884,526 N/A

Digital Health

($76,075,395)

Pan-Canadian Health Organizations 2023-24 76,075,395 N/A

Health Information

($88,739,969)

Pan-Canadian Health Organizations 2023-24 88,739,969 N/A

Canada Health Act

($1,649,138)

Canada Health Act Administration N/A 1,649,138 Low Need: HC's activities have focused on the administration of the Act, such as monitoring for compliance. On an annual basis, the federal Minister of Health is required to report to Parliament on the administration and operation of the Canada Health Act, which provides good oversight on this activity.

Medical Assistance in Dying

($1,075,395)

Medical Assistance in Dying N/A 1,075,395 Low Need: Program has been recently implemented. Furthermore, while the potential for conducting an evaluation will be examined in the future, parliamentary reporting requirements provide good oversight on this activity at this time.

Cancer Control

($52,075,395)

Pan-Canadian Health Organizations 2023-24 52,075,395 N/A

Patient Safety

($8,675,395)

Pan-Canadian Health Organizations 2023-24 8,675,395 N/A

Blood Systems, Organs, Tissue and Transplantation

($8,583,487)

Canadian Blood Services Contribution Programs 2022-23 8,583,487 N/A

Promoting Minority Official Languages in the Health Care Systems

($38,798,752)

Roadmap for Canada's Official Languages: Education Immigration Communities 2021-22 38,798,752 N/A

Brain Research

($13,174,646)

Brain Health N/A 13,174,646 Low Need: Last evaluation conducted in 2016-17; currently scheduled to sunset.

Thalidomide

($8,659,457)

Thalidomide Survivors Contribution Program 2019-20 8,659,457 N/A

Territorial Health Information Fund

($27,000,000)

Territorial Health Information Fund N/A 27,000,000 Low Need: Program will be sunsetting in 2020-21. An evaluation was completed in 2018-19.
Core Responsibility Health Protection and Promotion ($520,029,668)
Program Evaluations planned in the next five years Fiscal year of approval 2019-20 spending covered by evaluation ($) Rationale for not evaluating program or spending

Pharmaceutical Drugs

($54,868,350)

Drug Safety and Effectiveness Network (DSEN) 2019-20 652,039 N/A
Single Window Initiative 2020-21 - N/A
Veterinary Drugs 2021-22 - N/A
Human Drugs 2022-23 54,216,311 N/A

Biologics and Radiopharmaceutical Drugs

($39,629,681)

Single Window Initiative 2020-21 - N/A
Biologics and Radiopharmaceutical Drugs 2023-24 39,629,681 N/A

Medical Devices

($14,618,322)

Medical Devices 2019-20 14,618,322 N/A
Single Window Initiative 2020-21 - N/A

Natural Health Products

($15,954,791)

Natural Health Products Program 2020-21 15,954,791 N/A
Single Window Initiative 2020-21 - N/A

Food Safety and Nutrition

($61,436,386)

Canadian Food Safety Information Network 2022-23 - N/A
Food and Nutrition Program - Nutrition Policy 2022-23 61,436,386 N/A
Impact Assessment and Regulatory Processes 2022-23 - N/A
Food and Nutrition Program - Food Safety 2023-24 - N/A

Air Quality

($20,499,995)

Taking Action on Air Pollution 2020-21 19,299,995 N/A
Climate Change 2020-21 1,200,000 N/A

Climate Change

($4,842,642)

Climate Change 2020-21 3,688,281 N/A
Adapting to the Impacts of Climate Change 2021-22 1,154,361 N/A

Water Quality

($3,599,933)

Chemical Management Plan (including water quality) 2019-20 3,599,933 N/A

Health Impacts of Chemicals

($64,674,994)

Chemical Management Plan (including water quality) 2019-20 61,276,665 N/A
Impact Assessment and Regulatory Processes 2022-23 2,364,393 N/A
Consumer Product Safety 2022-23 500,000 N/A
Federal Contaminated Sites 2023-24 533,936 N/A

Consumer Product Safety

($31,868,948)

Single Window Initiative 2020-21 - N/A
Consumer Product Safety 2022-23 31,868,948 N/A

Workplace Hazardous Products

($3,587,196)

Workplace Hazardous Products 2019-20 3,587,196 N/A

Tobacco Control (including vaping)

($32,593,850)

HC's Tobacco Activities 2021-22 32,593,850 N/A

Controlled Substances

($38,661,752)

Canadian Drugs and Substances Strategy 2021-22 38,661,752 N/A

Cannabis

($67,832,012)

Cannabis Program 2022-23 67,832,012 N/A

Radiation Protection

($16,147,220)

Radiation Protection Activities 2020-21 16,147,220 N/A
Single Window Initiative 2020-21 - N/A

Pesticides

($34,553,720)

Pesticides Program 2020-21 34,553,720 N/A
Single Window Initiative 2020-21 - N/A

Specialized Health Services and Internationally Protected Persons Program

($14,659,876)

Specialized Health Services N/A 14,659,876

Low Need: No requirement to inform major policy or spending decisions.

Low Risk: Low enterprise risk. For one program component, Health Canada is the delivery agent rather than program owner (Employee Assistance Services - EAS). EAS has been accredited with the highest quality standard (gold) of the industry as set out by the Employee Assistance Society of North America (EASNA) as the Council of Accreditation (COA) carries out in-depth assessments of EAS' compliance with best practices in the industry.

Sex and Gender-based Analysis 2021-22 - N/A

Footnotes

Footnote 1

The evaluation of Canada's Tobacco Strategy is currently counted as two evaluations one covering Health Canada's activities and the other covering PHAC's activities. At the time of scoping the evaluation, these evaluations may be merged into one.

Return to footnote 1 referrer

Page details

Date modified: